Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality

Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Moradian, Negar, Gouravani, Mahdi, Salehi, Mohammad Amin, Heidari, Arash, Shafeghat, Melika, Hamblin, Michael R., Rezaei, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Libbey Eurotext 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792554/
https://www.ncbi.nlm.nih.gov/pubmed/33361013
http://dx.doi.org/10.1684/ecn.2020.0451
Descripción
Sumario:Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.

Ejemplares similares